The National Medical Products Administration (NMPA) has granted approval for Chengdu Chipscreen Pharmaceutical Co., Ltd (SHA: 688321)’s Category 1 drug Bilessglu (chiglitazar sodium) for use in combination with metformin to treat type 2 diabetes. This decision marks another milestone for the Chinese pharmaceutical company, which has developed chiglitazar as a novel non-TZD peroxisome proliferator-activated receptor (PPAR) α/γ/δ pan-agonist with deliberate moderate activity.
Chiglitazar is designed to act as an insulin sensitizer, offering potent insulin-sensitizing effects for patients with type 2 diabetes. This drug stands out globally as the first PPAR pan-agonist approved for the treatment of type 2 diabetes. In China, chiglitazar received its initial marketing approval as a monotherapy for type 2 diabetes in 2021 and was included in the National Reimbursement Drug List (NRDL) in 2023, making it accessible to a broader patient population.- Flcube.com
